Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease A Korean nationwide, multicenter, retrospective, observational, cohort study

Abstract

Evidence of the potential benefits of long-term oral branched-chain amino acid (BCAA) supplementation in reducing the severity of liver disease is limited. Patients who were diagnosed with liver cirrhosis with a Child-Pugh (CP) score of 8-10 were included. The BCAA group consumed BCAAs daily for at least 6 months, and the control group consumed a diet without BCAA. We analyzed the improvements based on the model for end-stage liver disease (MELD) score, CP score, incidence of cirrhosis-related complications, and event-free survival over 2 years. Among the 867 recruited patients, 307 (166 in the BCAA group and 141 in the control group) were analyzed. The BCAA group was divided into 3 subgroups, whose patients consumed 4.15g, 8.3g, or 12.45g of BCAAs daily for the analysis. There were significant differences in the CP score, albumin, and hepatic encephalopathy between the 2 groups at baseline. After matching the propensity scores, we analyzed patients in the BCAA-12.45g group (12.45g of BCAAs daily, n=41) and matched control group (n=41). The MELD score significantly improved in the BCCA-12.45g group compared to the matched control group (P=.004). The changes in the serum bilirubin level (P=.014) and CP score (P=.033) over time also differed significantly between the 2 groups. The incidence rates of cirrhosis-related complications (P=.973) and development of hepatocellular carcinoma (2 cases each) did not differ significantly between the 2 groups. Long-term oral BCAA supplementation has beneficial effects in patients with advanced liver cirrhosis. A further large-scale prospective study is needed to delineate these beneficial effects.